Journals | Policy | Permission

World Journal of Oncology

Case Report

Volume 14, Number 6, December 2023, pages 580-583

Osteoblastic Bone Reaction Developing During Treatment With Sintilimab and Bevacizumab in a Patient With KRAS^G12V-Mutant Lung Adenocarcinoma

Bone metastases, especially spinal metastasis, are common in lung cancer, whose metastatic lesions are usually osteolytic with poor prognosis [1]. Therefore, the lesions are usually osteolytic and hardly ever osteoblastic in radiological imaging or magnetic resonance imaging (MRI) scans [2]. Furthermore, osteoblastic metastases have mostly been reported in small-cell or adenocarcinoma of the lung [3, 4]. Unlike some tumors have spontaneous calcification, an osteoblastic reaction/response is a phenomenon in which new osteoblastic lesions appear that are not visible at baseline and are detected radiographically after treatment, such as targeted therapy and chemotherapy [5, 6]. This osteoblastic bone reaction has been described in reports of lung cancer; however, most of them were found in previously undetectable and undocumented bone metastases [7]. Compared with previous findings of osteoblastic bone reaction, we also found an osteoblastic bone reaction in a patient with lung adenocarcinoma treated with sintilimab and bevacizumab, which indicates responses to the therapy rather than disease progression. Therefore, we showed a positive therapeutic outcome of KRAS^G12V-mutant lung adenocarcinoma treated with sintilimab and bevacizumab, and we would like to share this with investigators in this field.

We report a 77-year-old smoking Asian male who presented with stage IV_B (T_2aN₂M_1c) adenocarcinoma of the right upper lobe with multiple bone, liver, and pulmonary metastases. In June 2022, he was admitted to our orthopedic department due to progressive back pain. Computed tomography (CT) confirmed multiple osteolytic bone metastases in the lumbar vertebrae and liver and pulmonary metastases (Fig. 1a-c). Then, the patient was further transferred to the oncology department for further management.

Click for large image

Figure 1. (a) Computed tomography (CT) scan showing a neoplasm in the right upper lobe (scale bar = 5 cm). (b) An enhanced CT scan confirmed the existence of a neoplasm (scale bar = 5 cm). (c) CT scans of the spine before treatment with sintilimab, bevacizumab, and chemotherapy showed multiple osteolytic lesions in the thoracic and lumbar vertebrae (scale bar = 5 cm). (d, e, f) An MRI study showed new pelvic and bilateral femoral metastases (scale bar = 5 cm). (g) CT scans of the spine showed marked osteoblastic activity and osteosclerosis in the vertebra with metastases after the treatment (scale bar = 5 cm). (h, i, j) The corresponding MRI scans of the spine after treatment. (h) T1W sagittal spin-echo sequence of the spine showed hypointense lesions in multiple thoracic and lumbar vertebrae. The T2W sagittal spin-echo sequence (i) and T2W sagittal spin-echo sequence with fat suppression (j) showed both hyperintense and hypointense lesions in multiple thoracic and lumbar vertebrae, which indicates osteoblastic bone lesions (scale bar = 5 cm).

Mutational analysis of the tumor revealed an activating KRAS^G12V mutation, and he subsequently completed eight cycles of sintilimab, and bevacizumab combined with paraplatin and pemetrexed for chemotherapy. In March 2023, he complained of pain in the bilateral hip, and a follow-up MRI scan showed new metastases in the pelvis and bilateral femur (Fig. 1d-f). He then received radiotherapy at the tumor site, which achieved pain relief. He continued immunotherapy, antiangiogenesis therapy, and chemotherapy. A CT scan 12 weeks later showed marked diffuse osteoblastic activity in the metastases in the lumbar vertebra and osteosclerosis surrounding the metastasis in the vertebrae with metastases (Fig. 1g). A corresponding MRI after the treatment confirmed the existence of abnormal osteoblastic bone lesions (Fig. 1h-j). Considering his improvement in bone pain, the increased osteosclerosis may be regarded as an osteoblastic response to immunotherapy [4, 5]. Therefore, the treatment was continued.

Currently, he is 1 year following the initial treatment and remains stable with the disease.

Bone metastasis, especially spinal metastasis, frequently develops from lung adenocarcinomas [1]. Kirsten rat sarcoma (KRAS) mutations occur in approximately 11% of the Asian population with lung cancer and account for 35% of lung adenocarcinomas [8]. Patients with KRAS mutations frequently have poor prognosis and low survival rates, whereas efficient therapies for KRAS-mutant non-small cell lung cancer (NSCLC) still fail to reach a consensus widely [9]. Among the various subtypes of mutations, KRAS^G12V mutations are predominant in smokers [8]. NSCLC with the KRAS^G12V mutation has distinct metastatic mechanisms compared with other subtypes, which can drive metastasis in a Wnt-dependent manner [8]. Moreover, a recent study revealed that the KRAS^G12V mutation in NSCLC can upregulate programmed death ligand 1 (PD-L1) expression and promote immune escape by regulating the transforming growth factor-β/epithelial-mesenchymal transition (EMT) signaling pathway, which can serve as a potential therapeutic target for KRAS mutations in NSCLC [10].

As an immune checkpoint inhibitor, sintilimab is a programmed cell death protein 1 (PD-1) inhibitor that is approved for patients with NSCLC, and studies have proven that squamous cell NSCLC exhibits a superior response to sintilimab compared with adenocarcinoma [11]. However, the mechanism by which sintilimab induces an osteoblastic response in our patients with spinal metastases from lung adenocarcinoma is unclear and needs further investigation. Bone metastasis, especially spinal metastasis, is frequently related to lung cancer, which is usually osteolytic due to enhanced osteoclast differentiation [1, 12, 13]. Activated osteoclasts have been shown to be associated with activation of the PD-1 pathway, whose blockade can inhibit osteoclast formation and cancer-related pain in bones [14, 15]. Considering the activation of the Wnt signaling pathway in NSCLC with the KRAS^G12V mutation, we hypothesized that PD-1 inhibition can inhibit osteoclastogenesis and facilitate Wnt-dependent osteogenesis in cancer bone metastases during bone remodeling [8, 16, 17]. Therefore, osteoblastosis can be regarded as an indirect sign of the response to efficient PD-1 inhibition within bone metastases of KRAS^G12V-mutant lung adenocarcinoma.

Increasing evidence has demonstrated that inflammation, especially chronic inflammation, highly correlates with cancer, which can promote oncogenesis by upregulating immune checkpoints to induce a state of immunosuppression in the tumor microenvironment [18, 19]. Thus, immunotherapy, such as immune checkpoint inhibitors, has emerged as an effective tool for disease control in patients with advanced NSCLC; however, antiangiogenic therapy also plays a vital role in fighting cancers [20, 21]. In our case, we showed promising clinical outcomes by synergistically administering immunotherapy and antiangiogenesis combined with chemotherapy. Although the safety of the regimen is acceptable in patients, further studies are still needed to discover more promising and effective chemotherapy-free options for the treatment of patients with advanced NSCLC, especially KRAS^G12V-mutant lung adenocarcinoma, to improve therapeutic efficacy and tolerability. Therefore, it is important for clinicians to be aware of this phenomenon of osteoblastic reaction/response, which may predict a good response to treatment, especially immunotherapy with PD-1 inhibitors, for patients with KRAS^G12V-mutant lung adenocarcinoma.

In conclusion, this case report documents a rare osteoblastic bone reaction developing during treatment with sintilimab and bevacizumab in a patient with KRAS^G12V-mutant lung adenocarcinoma, which represents a good response to treatment rather than disease progression. However, our case has several limitations. First, we only reported a phenomenon and preliminarily investigated its potential mechanisms; thus, a mechanistic study in depth is needed. Second, our study had a limited number of patients; thus, a large-scale study is needed. These limitations are the bases and directions for further studies. Therefore, to compensate for these shortcomings, further studies should be conducted to verify our findings.

Acknowledgments

None to declare.

Financial Disclosure

This work was supported by the Natural Science Foundation of Shandong Province (grant no. ZR2023QH517; ZR2022QH252; ZR2020QH077; ZR2020MH087); Shandong Qianfoshan Hospital Cultivation Fund (QYPY2019NSFC1011); and Academic Promotion Program of Shandong First Medical University (2019LJ001).

Conflict of Interest

The authors declared no conflict of interest.

Informed Consent

This study was approved by our institution, and written informed consent was obtained from the patient.

Author Contributions

XJM, CJC and XZ participated in the drafting, writing, and revising of the manuscript. JWZ, WHX, YBQ, JKL, and QWM participated in the data selection and analysis. CJC, LZ, and YY contributed to the study concept and acquired and analyzed the data. All authors contributed to the drafting of the manuscript and figure preparation.

Data Availability

The data sets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

1. Chen CJ, Yan TB, Liu YD, Wang Y, Zhao X, Qi YB, et al. Multiple myeloma rather than metastatic lung cancer: an unexpected cause of spinal cord compression. World Journal of Oncology. 2023;14(5):438-442.
2. Chen C, Ma Q, Qi Y, Wu Y, Li J, Ren Y, et al. Osteolytic schwannoma in an older patient with lumbar degenerative disk disease: a case report. HSS Journal®. 15563316231200862.
3. Napoli LD, Hansen HH, Muggia FM, Twigg HL. The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes. Radiology. 1973;108(1):17-21.
   doi pubmed
4. Lind JS, Postmus PE, Smit EF. Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report. J Thorac Oncol. 2010;5(4):554-557.
   doi pubmed
5. Comito F, Ambrosini V, Sperandi F, Melotti B, Ardizzoni A. Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma. Anticancer Drugs. 2018;29(10):1026-1029.
   doi pubmed
6. Chen C, Ren Y, Qi Y, Zhang G, Hu H, Zhang K, Wu Y, et al. Congenital lumbosacral malformations with low-grade neuroepithelial tumor causing progressive postpoliomyelitis paralytic limb. Ann Neurol. 2023;94(1):160-162.
   doi pubmed
7. Fink C, Hasan B, Deleu S, Pallis AG, Baas P, O'Brien M. High prevalence of osteoblastic bone reaction in computed tomography scans of an European Organisation for Research and Treatment of Cancer prospective randomised phase II trial in extensive stage small cell lung cancer. Eur J Cancer. 2012;48(17):3157-3160.
   doi pubmed
8. Hung PS, Huang MH, Kuo YY, Yang JC. The inhibition of wnt restrain KRAS(G12V)-driven metastasis in non-small-cell lung cancer. Cancers (Basel). 2020;12(4):837.
   doi pubmed pmc
9. Ricciuti B, Leonardi GC, Metro G, Grignani F, Paglialunga L, Bellezza G, Baglivo S, et al. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Rev Respir Med. 2016;10(1):53-68.
   doi pubmed
10. Pan LN, Ma YF, Li Z, Hu JA, Xu ZH. KRAS G12V mutation upregulates PD-L1 expression via TGF-beta/EMT signaling pathway in human non-small-cell lung cancer. Cell Biol Int. 2021;45(4):795-803.
    doi pubmed
11. Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15(5):816-826.
    doi pubmed
12. da Silva GT, Bergmann A, Santos Thuler LC. Prognostic factors in patients with metastatic spinal cord compression secondary to lung cancer: a systematic review of the literature. Eur Spine J. 2015;24(10):2107-2113.
    doi pubmed
13. Wang M, Zhao M, Guo Q, Lou J, Wang L. Non-small cell lung cancer cell-derived exosomal miR-17-5p promotes osteoclast differentiation by targeting PTEN. Exp Cell Res. 2021;408(1):112834.
    doi pubmed
14. Tai YT, Cho SF, Anderson KC. Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1. Front Immunol. 2018;9:1822.
    doi pubmed pmc
15. Wang K, Gu Y, Liao Y, Bang S, Donnelly CR, Chen O, Tao X, et al. PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. J Clin Invest. 2020;130(7):3603-3620.
    doi pubmed pmc
16. Chen C, Fu L, Luo Y, Zeng W, Qi X, Wei Y, Chen L, et al. Engineered exosome-functionalized extracellular matrix-mimicking hydrogel for promoting bone repair in glucocorticoid-induced osteonecrosis of the femoral head. ACS Appl Mater Interfaces. 2023;15(24):28891-28906.
    doi pubmed
17. Wang Q, Miao Y, Qian Z, Chen L, Lu T, Xu Y, Jiang X, et al. MicroRNA-15a-5p plays a role in osteogenic MC3T3-E1 cells differentiation by targeting PDCD4 (programmed cell death 4) via Wnt/beta-catenin dependent signaling pathway. Bioengineered. 2021;12(1):8173-8185.
    doi pubmed pmc
18. Sara A, Ruff SM, Noonan AM, Pawlik TM. Real-world use of immunotherapy for hepatocellular carcinoma. Pragmat Obs Res. 2023;14:63-74.
    doi pubmed pmc
19. Chen C, Si M, Gao X, Wang W, Wang S, Pan X. Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options. Postepy Dermatol Alergol. 2022;39(3):545-552.
    doi pubmed pmc
20. Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021;16(4):643-652.
    doi pubmed
21. Chen C, Wang S, Chen J, Liu X, Zhang M, Wang X, Xu W, et al. Escin suppresses HMGB1-induced overexpression of aquaporin-1 and increased permeability in endothelial cells. FEBS Open Bio. 2019;9(5):891-900.
    doi pubmed pmc

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

World Journal of Oncology is published by Elmer Press Inc.